India is one of the few large medical device markets where the regulatory pathway and the commercial pathway are genuinely separable problems. Clearing CDSCO tells you that you may sell. It tells you almost nothing about whether you will.

The regulatory layer

Device classification drives everything downstream. Risk class determines the licence route, the documentation burden and whether a registered Indian agent is sufficient or a local manufacturing licence becomes the better answer. The classification lists have expanded steadily, so devices that entered under a lighter regime a few years ago are not necessarily on that regime today.

Two points are worth planning around. First, the authorised agent holds the licence, which makes the choice of agent a strategic decision rather than an administrative one. Second, quality documentation from an established market shortens the file but does not remove the need for India specific labelling, import registration and post market commitments.

The buyers who actually set volume

Private hospital chains move quickly and negotiate hard on price. Government procurement moves slowly, buys in size and sets reference pricing that the private market then benchmarks against. Ignoring the public channel because it is slow usually means accepting whatever price the tenders establish.

• Central and state tenders reward local presence, service depth and demonstrated supply reliability over clinical differentiation.

• Price capping on selected categories is a live risk and should be modelled as a scenario, not an exception.

• Distributor structures vary by state and a single national distributor rarely covers the country well.

Where the margin leaks

The two most common surprises are service economics and channel conflict. Service is not a warranty line item in India, it is a purchasing criterion, and hospitals will discount a superior device that cannot be serviced within a day. Channel conflict arises when a national distributor is appointed before the tender strategy is set, because tender participation often requires a different entity structure than private sales.

A workable entry shape

For most mid sized manufacturers the sequence that holds up is: classify and file early, appoint an agent whose incentives you can control, win two or three reference accounts in the private segment, then use that installed base and service record to qualify for public tenders. Reversing that order is possible but it means competing on price before you have any evidence to defend it with.